Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

66.16USD
24 Feb 2017
Change (% chg)

$0.31 (+0.47%)
Prev Close
$65.85
Open
$65.65
Day's High
$66.16
Day's Low
$65.63
Volume
8,444,253
Avg. Vol
11,025,544
52-wk High
$66.16
52-wk Low
$49.63

MRK

Chart for MRK

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $182,412.20
Shares Outstanding(Mil.): 2,757.14
Dividend: 0.47
Yield (%): 2.84

Financials

  MRK Industry Sector
P/E (TTM): 32.39 28.84 29.63
EPS (TTM): 2.04 -- --
ROI: -- 13.44 12.96
ROE: -- 14.34 14.11

BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases

* In first phase 3 trial, Merck's investigational inactivated varicella zoster virus vaccine (V212) reduced the incidence of confirmed herpes zoster cases by an estimated 64 percent in immunocompromised subjects

Feb 24 2017

BRIEF-Merck to record $2.9 bln impairment charge related to uprifosbuvir program - SEC filing

* On Feb 17, determined that it will record intangible asset impairment charge related to research program for MK-3682, uprifosbuvir - SEC filing

Feb 23 2017

Merck drug prevents serious infection after marrow transplant: study

An experimental Merck & Co drug succeeded in preventing clinically serious cytomegalovirus (CMV) following bone marrow transplant and was associated with a lower death rate compared with placebo in a late state study, the company said.

Feb 23 2017

BRIEF-Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating Imprime PGG, Merck's Keytruda

* Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating imprime pgg and merck’s keytruda® (pembrolizumab)

Feb 23 2017

Merck stopping late stage study as another Alzheimer's drug fails

Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.

Feb 14 2017

UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails

Feb 14 Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease.

Feb 14 2017

Merck to halt study of mild to moderate Alzheimer's drug

Feb 14 Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness.

Feb 14 2017

BRIEF-Merck announces Epoch study of Verubecestat

* Merck announces epoch study of verubecestat for the treatment of people with mild to moderate alzheimer's disease to stop for lack of efficacy

Feb 14 2017

BRIEF-Merck's doravirine meets primary efficacy endpoint in pivotal phase 3 trial

* Merck's doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (nnrti) for the treatment of hiv-1 infection, met primary efficacy endpoint in pivotal phase 3 trial

Feb 14 2017

BRIEF-Capital World Investors reports 5.1 pct passive stake in Merck & Co as on Dec 30 - SEC Filing

* Capital World Investors reports 5.1 percent passive stake in Merck & Co Inc as on December 30, 2016 - SEC Filing Source text: [http://bit.ly/2kkIx8A] Further company coverage:

Feb 13 2017

More From Around the Web

Competitors

Earnings vs. Estimates